ANXA1 and melanoma: Other significantly reduced proteins include TRAIL, TGFR-2, ANXA1, SPARC, FURIN, GPNMB, and ERBB2, all of which play roles in melanoma progression, immune modulation, or resistance to targeted therapies [29,30].